MCID: OPT009
MIFTS: 50

Optic Neuritis malady

Categories: Rare diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Optic Neuritis

Aliases & Descriptions for Optic Neuritis:

Name: Optic Neuritis 12 50 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1210
ICD10 33 H46 H46.9
ICD9CM 35 377.3 377.30
MeSH 42 D009902
NCIt 47 C84950
UMLS 69 C0029134

Summaries for Optic Neuritis

NIH Rare Diseases : 50 optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. the condition may cause sudden, reduced vision in the affected eye(s). while the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis, drug toxicity and deficiency of vitamin b-12. vision often returns to normal within 2-3 weeks without treatment. in some cases, corticosteroids are given to speed recovery. if known, the underlying cause should be treated. last updated: 1/11/2011

MalaCards based summary : Optic Neuritis is related to neuromyelitis optica and transverse myelitis, and has symptoms including eye manifestations An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Toxoplasmosis and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and t cells, and related phenotypes are behavior/neurological and hematopoietic system

Disease Ontology : 12 An optic nerve disease that results_in inflammation located in optic nerve which may cause a complete or partial loss of vision.

Wikipedia : 71 Optic neuritis is a demyelinating inflammation of the optic nerve. It is also known as optic papillitis... more...

Related Diseases for Optic Neuritis

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 221)
id Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 11.6
2 transverse myelitis 11.3
3 optic papillitis 11.2
4 neuritis 11.0
5 optic nerve disease 10.9
6 retinitis 10.5
7 bilateral parasagittal parieto-occipital polymicrogyria 10.3 HLA-DRB1 TNF
8 mirizzi syndrome 10.3 HLA-DRB1 TNF
9 autosomal dominant intermediate charcot-marie-tooth 10.2 HLA-DRB1 TNF
10 distal trisomy 14q 10.2 HLA-DRB1 TNF
11 neuropathy 10.2
12 crest syndrome 10.2 AQP4 MBP
13 swine influenza 10.2 HLA-DRB1 TNF
14 t-cell prolymphocytic leukemia 10.2 CCR5 TNF
15 cervical adenoid basal carcinoma 10.2 HLA-DRB1 MBP MOG
16 alopecia-intellectual disability syndrome 10.2 MBP MOG PLP1
17 myelitis 10.2
18 trichomalacia 10.2 AQP4 MBP TNF
19 gastric dilatation 10.2 AQP4 MBP TNF
20 angiomatosis, diffuse corticomeningeal, of divry and van bogaert 10.2 HLA-DRB1 TNF
21 clear cell adenoma 10.2 AQP4 MBP MOG
22 schwannoma of twelfth cranial nerve 10.2 AQP4 MBP MOG
23 ischemic optic neuropathy 10.2
24 parasitic helminthiasis infectious disease 10.2 HLA-DRB1 MOG TNF
25 clostridium difficile colitis 10.1 HLA-DRB1 TNF
26 submandibular gland disease 10.1 MAG TNF
27 penis agenesis 10.1 HLA-DRB1 MOG
28 spondylometaphyseal dysplasia east-african type 10.1 LTA TNF
29 allergic contact dermatitis of eyelid 10.1 AQP4 MOG MT-ND4
30 thymic neuroendocrine carcinoma 10.1 LTA TNF
31 human immunodeficiency virus infectious disease 10.1 HLA-DRB1 TNF
32 childhood brainstem astrocytoma 10.1 AQP4 MAG MBP
33 systemic lupus erythematosus 10.1
34 lupus erythematosus 10.1
35 craniorachischisis 10.1 MBP MPZ
36 persistent mullerian duct syndrome 10.1 MBP MOG PLP1 TNF
37 drug dependence 10.1 LTA TNF
38 niemann-pick disease 10.1 AQP4 HLA-DRB1 MBP MOG
39 articulation disorder 10.1 HLA-DRB1 MBP MOG TNF
40 kernicterus due to isoimmunization 10.1 HLA-DRB1 LTA TNF
41 idiopathic hypertrophic pachymeningitis 10.1 LTA TNF
42 neonatal jaundice 10.1 AQP4 MBP MOG TNF
43 vestibule of mouth cancer 10.0 LTA TNF
44 hepatitis 10.0
45 encephalitis 10.0
46 deafness, autosomal recessive 67 10.0 HLA-DRB1 LTA TNF
47 intracranial hemorrhage in brain cerebrovascular malformations 10.0 HLA-DRB1 LTA TNF
48 parotid gland cancer 10.0 AQP4 HLA-DRB1 MOG TNF
49 atrial septal defect 6 10.0 HLA-DRB1 LTA TNF
50 nerve fibre bundle defect 10.0 AQP4 MBP MOG MT-ND4

Comorbidity relations with Optic Neuritis via Phenotypic Disease Network (PDN):


Hypertension, Essential Temporal Arteritis

Graphical network of the top 20 diseases related to Optic Neuritis:



Diseases related to Optic Neuritis

Symptoms & Phenotypes for Optic Neuritis

UMLS symptoms related to Optic Neuritis:


eye manifestations

MGI Mouse Phenotypes related to Optic Neuritis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 AQP4 CCR5 CNTF LTA MAG MBP
2 hematopoietic system MP:0005397 10.02 AQP4 CCR5 CNTF LTA MAG MBP
3 homeostasis/metabolism MP:0005376 9.96 SOD3 TNF AQP4 CCR5 CNTF LTA
4 immune system MP:0005387 9.9 MPZ PLP1 SOD3 TNF AQP4 CCR5
5 nervous system MP:0003631 9.65 MAG MBP MOG MPZ PLP1 TNF
6 vision/eye MP:0005391 9.17 AQP4 CCR5 LTA MBP MOG PLP1

Drugs & Therapeutics for Optic Neuritis

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
4
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2 147245-92-9 3081884
5
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
6
Interferon beta-1a Approved, Investigational Phase 4,Phase 3 145258-61-3 6438354
7
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
10 Adrenocorticotropic Hormone Phase 4,Early Phase 1
11 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 beta-endorphin Phase 4,Early Phase 1
16 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
17 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Melanocyte-Stimulating Hormones Phase 4,Early Phase 1
22 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
23 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
24 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
27 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
28 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
29 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Analgesics Phase 4
34 Topoisomerase Inhibitors Phase 4
35 Antimetabolites Phase 4,Phase 3,Phase 2
36 Vitamin B Complex Phase 4,Phase 1
37 Anti-Infective Agents Phase 4,Phase 2,Phase 3
38 Antiviral Agents Phase 4,Phase 2,Phase 3
39 Interferon-beta Phase 4,Phase 2,Phase 3
40 interferons Phase 4,Phase 2,Phase 3
41 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3
42 Dermatologic Agents Phase 4,Phase 2
43 Anti-Bacterial Agents Phase 4,Phase 2
44 Antibiotics, Antitubercular Phase 4
45 Folate Nutraceutical Phase 4,Phase 1
46 Vitamin B9 Nutraceutical Phase 4,Phase 1
47
Simvastatin Approved Phase 3 79902-63-9 54454
48
4-Aminopyridine Approved Phase 2, Phase 3 504-24-5 1727
49
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
50
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696

Interventional clinical trials:

(show top 50) (show all 93)
id Name Status NCT ID Phase
1 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4
2 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4
3 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4
4 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4
5 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
6 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4
7 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
8 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4
9 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4
10 A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a Withdrawn NCT00771043 Phase 4
11 Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Withdrawn NCT00037115 Phase 4
12 Simvastatin Treatment of Patients With Acute Optic Neuritis Unknown status NCT00261326 Phase 3
13 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3
14 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
15 Optic Neuritis Recovery After Oral or IV Corticosteroids Completed NCT01524250 Phase 2, Phase 3
16 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon) Completed NCT00856635 Phase 3
17 Ampyra for Optic Neuritis in MS Completed NCT01337986 Phase 2, Phase 3
18 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3
19 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3
20 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Recruiting NCT01962571 Phase 3
21 Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study) Recruiting NCT02376881 Phase 3
22 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Recruiting NCT01892345 Phase 3
23 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Recruiting NCT02073279 Phase 3
24 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3
25 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
26 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3
27 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
28 MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) Terminated NCT01647880 Phase 2, Phase 3
29 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3
30 Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis Withdrawn NCT01337427 Phase 3
31 Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2
32 Amiloride Clinical Trial In Optic Neuritis Unknown status NCT01802489 Phase 2
33 Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve Unknown status NCT01879527 Phase 2
34 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
35 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2
36 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
37 BIIB033 In Acute Optic Neuritis (AON) Completed NCT01721161 Phase 2
38 Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis Completed NCT00355095 Phase 2
39 Neuroprotection With Phenytoin in Optic Neuritis Completed NCT01451593 Phase 2
40 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2
41 Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) Completed NCT00395200 Phase 1, Phase 2
42 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2
43 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2
44 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2
45 Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis Completed NCT00772525 Phase 2
46 Gypenosides Treatment for Optic Neuritis Recruiting NCT02976766 Phase 2
47 Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer and Visual Field in Patients With an Acute Optic Neuritis Recruiting NCT02939937 Phase 2
48 Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) Recruiting NCT02521311 Phase 2
49 Hematopoietic Stem Cell Transplant in Devic's Disease Recruiting NCT00787722 Phase 1, Phase 2
50 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Active, not recruiting NCT03062579 Phase 1, Phase 2

Search NIH Clinical Center for Optic Neuritis

Cochrane evidence based reviews: optic neuritis

Genetic Tests for Optic Neuritis

Anatomical Context for Optic Neuritis

MalaCards organs/tissues related to Optic Neuritis:

39
Eye, Brain, T Cells, Testes, Pituitary, Myeloid, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Neuritis:

18
Optic Nerve Which May Cause A Complete Or Partial Loss Of Vision

Publications for Optic Neuritis

Articles related to Optic Neuritis:

(show top 50) (show all 734)
id Title Authors Year
1
Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. ( 28057643 )
2017
2
Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. ( 27844165 )
2017
3
Optic neuritis: the eye as a window to the brain. ( 27906756 )
2017
4
Neuroprotection and visual function after optic neuritis. ( 27941524 )
2017
5
Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis. ( 27862614 )
2017
6
Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. ( 27171375 )
2016
7
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. ( 27159992 )
2016
8
Anti-myelin Oligodendrocyte Glycoprotein Antibodies in a Patient with Recurrent Optic Neuritis Involving the Cerebral White Matter and Brainstem. ( 27181546 )
2016
9
A case of multiple evanescent white dot syndrome misdiagnosed as optic neuritis: Differential diagnosis for the neurologist. ( 27114663 )
2016
10
Optic neuritis secondary to antiandrogen therapy. ( 28039596 )
2016
11
Case-centered Analysis of Optic Neuritis After Vaccines. ( 27069066 )
2016
12
Pediatric Optic Neuritis Prospective Outcomes Study. ( 27176554 )
2016
13
Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. ( 26163068 )
2016
14
Optic neuritis as an initial presentation of primary SjAPgren syndrome: A case report and literature review. ( 27858858 )
2016
15
Eleven episodes of recurrent optic neuritis of the same eye for 22 years eventually diagnosed as neuromyelitis optica spectrum disorder. ( 27919493 )
2016
16
Ultrasonic Elastography Evaluation in Optic Neuritis. ( 27628306 )
2016
17
Distinguishing ischaemic optic neuropathy from optic neuritis by ganglion cell analysis. ( 27364519 )
2016
18
Serial Diffusion Tensor Imaging of the Optic Radiations after Acute Optic Neuritis. ( 27555964 )
2016
19
Optic Neuritis in a Patient with Bickerstaff's Brainstem Encephalitis. ( 27486938 )
2016
20
Pseudo-subarachnoid hemorrhage and optic neuritis in an 18-year-old girl with sodium valproate overdose. ( 27904589 )
2016
21
Unilateral Optic Neuritis: A Rare Complication after Measles-Mumps-Rubella Vaccination in a 30-Year-Old Woman. ( 27195163 )
2016
22
Valproic acid and ASK1 deficiency ameliorate optic neuritis and neurodegeneration in an animal model of multiple sclerosis. ( 28040492 )
2016
23
A prospective cohort study of vitamin D in optic neuritis recovery. ( 27037181 )
2016
24
Alveolar rhabdomyosarcoma of the sphenoid sinus mimicking optic neuritis presenting with intermittent visual loss in an adult. ( 27932889 )
2016
25
Optic neuritis in multiple sclerosis: Looking from a patient's eyes. ( 27432178 )
2016
26
Cortical functional modifications following optic neuritis. ( 27207448 )
2016
27
Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. ( 27582898 )
2016
28
Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. ( 27423624 )
2016
29
20/40 or Better Visual Acuity After Optic Neuritis: Not as Good as We Once Thought? ( 27472185 )
2016
30
Structural Alterations of Segmented Macular Inner Layers in Aquaporin4-Antibody-Positive Optic Neuritis Patients in a Chinese Population. ( 27336477 )
2016
31
Optic neuritis with secondary retinal venous stasis in a case of abdominal tuberculosis. ( 27843238 )
2016
32
Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations. ( 27046292 )
2016
33
Retinal ganglion cell and axonal loss in optic neuritis: risk factors and visual functions. ( 27858936 )
2016
34
Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis. ( 27301383 )
2016
35
Optic neuritis with TNF alpha antagonists. ( 27213191 )
2016
36
Clinical Reasoning: Left hemiparesis, ataxia, and optic neuritis in a child previously treated for pineoblastoma. ( 27163667 )
2016
37
Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. ( 27049558 )
2016
38
Occurrence of Optic Neuritis and Cervical Cord Schwannoma with Charcot-Marie-Tooth Type 4B1 Disease. ( 27162595 )
2016
39
Combined brain and anterior visual pathways' MRIs assist in early identification of neuromyelitis optica spectrum disorder at onset of optic neuritis. ( 27804015 )
2016
40
Pediatric optic neuritis. ( 27572862 )
2016
41
Treatment Choices in Optic Neuritis: Corticosteroids, Intravenous Immunoglobulin, Plasma Exchange, or Other? ( 27096487 )
2016
42
Loss of Nrf2 exacerbates the visual deficits and optic neuritis elicited by experimental autoimmune encephalomyelitis. ( 28050123 )
2016
43
Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis. ( 27806869 )
2016
44
Occurrence of Asymptomatic Acute Neuromyelitis Optica Spectrum Disorder-Typical Brain Lesions during an Attack of Optic Neuritis or Myelitis. ( 27936193 )
2016
45
A Case of Optic Neuritis Concomitant with Pituitary Tumor During Pregnancy. ( 27373939 )
2016
46
Recurrent myelopathy and optic neuritis associated with systemic lupus erythematosus. ( 27381135 )
2016
47
Optic Nerve Sheath Meningioma Masquerading as Optic Neuritis. ( 26904329 )
2016
48
Mucocele After Orbital Fracture Repair Masquerading as Optic Neuritis. ( 27171955 )
2016
49
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice. ( 27122964 )
2016
50
Bilateral optic neuritis in a boy - More than the eyes. ( 27326949 )
2016

Variations for Optic Neuritis

Expression for Optic Neuritis

Search GEO for disease gene expression data for Optic Neuritis.

Pathways for Optic Neuritis

Pathways related to Optic Neuritis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.82 CCR5 HLA-DRB1 TNF
2 11.65 AQP4 PLP1 TNF
3 11.49 HLA-DRB1 MAG MPZ
4 11.34 AQP4 MAG MBP TNF
5 10.8 HLA-DRB1 TNF
6 9.7 MAG MBP PLP1

GO Terms for Optic Neuritis

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.85 AQP4 CCR5 HLA-DRB1 LTA MAG MBP
2 external side of plasma membrane GO:0009897 9.26 AQP4 CCR5 HLA-DRB1 TNF
3 myelin sheath GO:0043209 8.92 MAG MBP MPZ PLP1

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.65 CCR5 HLA-DRB1 LTA MBP TNF
2 negative regulation of growth of symbiont in host GO:0044130 9.43 LTA TNF
3 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.4 MAG MPZ
4 central nervous system myelination GO:0022010 9.37 MAG PLP1
5 myelination GO:0042552 9.33 MBP MPZ PLP1
6 axon ensheathment GO:0008366 9.32 MBP PLP1
7 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 8.96 LTA TNF
8 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 8.62 LTA TNF

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.16 LTA TNF
2 structural constituent of myelin sheath GO:0019911 8.96 MBP PLP1
3 virus receptor activity GO:0001618 8.8 CCR5 HLA-DRB1 MOG

Sources for Optic Neuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....